Oncocyte Corporation

Good day, and welcome to the Oncocite conference call to discuss the second quarter 2022 financial results. Today's call is being recorded. At this time, I would like to turn the call over to Caroline Corner with Twig Investor Relations.

Please go ahead.

Thank you, Operator, and thank you, everyone, for joining us on today's conference call to discuss Oncocite's second quarter 2022 financial results. If you have not seen today's financial results press releases, please visit the company's website on the Investors page. Joining me on today's call are Ronnie Andrews, President and Chief Executive Officer, and Anish John, Chief Financial Officer. I would like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events. Any statements that are not historical fact are forward-looking statements. We encourage you to review this company's SEC filings, including, without limitation, the company's Forms 10-K and 10-Qs, which identify the specific risk factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, risks inherent in the development and or the commercialization of potential diagnostic tests, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supply blood sample analytics system to provide consistent and precise analytic results on a commercial scale, the need to obtain third-party reimbursements for patients' use of any diagnostic tests the company commercializes, our need and ability to obtain future capital, the maintenance of IP rights, risks inherent in the strategic transaction, such as failure to realize anticipated benefits, legal, regulatory, or political changes in the applicable jurisdictions, accounting and quality controls, greater than estimated allocations of resources to develop and commercialize technologies, or failure to maintain any laboratory accreditation or certification, and uncertainties associated with the COVID-19 pandemic and its possible effects on our operations. Therefore, actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. Oncocite expressly disclaims any intent or obligation to update these forward-looking statements, except as otherwise may be required under applicable law. With that, I'll turn the call over to Ronnie.